SNTI
What one share of Senti Biosciences Holdings holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches.
Senti Biosciences Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | −$0.13 |
|---|---|
| Profit | −$1.71 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.31 |
| Cash and investments | $0.21 |
| Book value | −$0.11 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$189.95 | $19.03 | −$137.96 | — | −$374.97 |
| 2022 | — | −$22.29 | $15.85 | −$29.21 | — | $28.88 |
| 2023 | — | −$16.01 | $2.71 | −$14.52 | — | $14.64 |
| 2024 | — | −$12.04 | $0.01 | −$9.01 | — | $5.31 |
| 2025 | $0.00 | −$2.73 | $0.01 | −$1.94 | — | $0.18 |